Healthcare [ 5/13 ] | Biotechnology [ 44/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 22, 24 | -0.12 Decreased by -300% | -0.09 Decreased by -33.33% |
| Oct 31, 23 | 0.03 Increased by +121.43% | -0.11 Increased by +127.27% |
| Aug 2, 23 | -0.08 Increased by +57.89% | -0.11 Increased by +27.27% |
| May 3, 23 | -0.13 Increased by +38.1% | -0.1 Decreased by -30% |
| Mar 2, 23 | 0.06 Increased by +119.35% | -0.02 Increased by +400% |
| Nov 3, 22 | -0.14 Increased by +66.67% | -0.17 Increased by +17.65% |
| Aug 4, 22 | -0.19 Increased by +57.78% | -0.19 |
| May 5, 22 | -0.21 Increased by +38.24% | -0.22 Increased by +4.55% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 34.36 M Decreased by -22.22% | -28.8 M Decreased by -369.3% | Decreased by -83.82% Decreased by -446.22% |
| Sep 30, 23 | 56.39 M Increased by +1.03 K% | 6.63 M Increased by +127.73% | Increased by +11.76% Increased by +102.45% |
| Jun 30, 23 | 22.33 M Increased by +784.13% | -17.12 M Increased by +36.44% | Decreased by -76.66% Increased by +92.81% |
| Mar 31, 23 | 11.37 M Increased by +2.33 K% | -26.77 M Increased by +4.62% | Decreased by -235.49% Increased by +96.07% |
| Dec 31, 22 | 44.18 M Increased by +4.19 K% | 10.7 M Increased by +129.52% | Increased by +24.21% Increased by +100.69% |
| Sep 30, 22 | 4.99 M Increased by +325.06% | -23.91 M Increased by +45.15% | Decreased by -479.46% Increased by +87.1% |
| Jun 30, 22 | 2.53 M Increased by +92.38% | -26.94 M Increased by +40.39% | Decreased by -1.07 K% Increased by +69.01% |
| Mar 31, 22 | 468 K Decreased by -92.89% | -28.07 M Increased by +15.33% | Decreased by -6 K% Decreased by -1.09 K% |
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.